clickNsettle.com, Inc. and Cardo Medical, LLC Announce Completion of Merger

MIAMI and LOS ANGELES, Sept. 2 /PRNewswire-FirstCall/ -- Cardo Medical,
LLC, a company engaged in the development of orthopedic medical devices, and
clickNsettle.com, Inc., a publicly-traded company with no active operations
("CKST"), completed a merger on August 29, 2008, pursuant to a merger
agreement providing for the merger of Cardo with and into Cardo Acquisition,
LLC, a wholly-owned subsidiary of CKST. Cardo will continue as the surviving
entity in the merger and as a wholly-owned subsidiary of CKST.
As previously reported, on or about the signing of the merger agreement on
June 18, 2008, a group of investors led by Dr. Phillip Frost, Chairman and
Chief Executive Officer of Opko Health, Inc., invested approximately $13.0
million in Cardo in exchange for units of Cardo's membership interests.
Cardo used approximately $9.7 million of the proceeds from these investments
to close on the acquisition of the remaining outstanding equity interests of
three partially owned subsidiaries of Cardo (Accelerated Innovation, LLC,
Cervical Xpand, LLC, and Uni-Knee, LLC), and Cardo expects to use the
remaining funds to accelerate its research and product development.
Under the terms of the merger agreement, at the closing of the merger,
each Cardo unit issued and outstanding was converted into and exchanged for
the right to receive 667,204.70995 shares of common stock of CKST. As a
result of the merger, CKST's stockholders own approximately 5.5% of the
combined company on a fully diluted basis, the members of Cardo, excluding the
new investors, own approximately 64.8% of the combined company on a fully
diluted basis, the new investors own approximately 28.5% of the combined
company on a fully diluted basis, and option holders of Cardo own
approximately 1.2% of the combined company on a fully diluted basis.
In connection with the consummation of the merger, CKST expects to change
its name from "clickNsettle.com, Inc." to "Cardo Medical, Inc." CKST's
trading symbol is "CKST.OB," which the company expects to change in connection
with the name change. CKST intends to apply to have its shares listed on the
American Stock Exchange.
In addition, on the tenth day after filing and transmitting an Information
Statement pursuant to Section 14(f) of the Securities Exchange Act of 1934 and
Rule 14f-1 thereunder (approximately September 12, 2008), the Board of
Directors of Cardo initially will consist of five directors to be appointed by
Dr. Andrew Brooks and two directors to be appointed by Dr. Frost. Dr. Brooks,
an orthopedic surgeon, will serve as Chief Executive Officer of the combined
company and as its Chairman of the Board. The company is now headquartered in
Los Angeles, California.
Dr. Brooks commented, "We are pleased to have completed our merger, and
are excited to be working with Dr. Frost and his group as we grow our company
into a significant and important source of innovative product development and
distribution for orthopedic reconstructive and spine surgical devices. I am
personally excited and grateful to be in a business which offers the ability
to improve the quality of life and functional abilities of so many patients."
Dr. Frost added, "We are thrilled to partner with the management team of
Cardo Medical and look forward to working with them as they build their
exciting company into a world class orthopedic and spinal device business."
Glenn L. Halpryn, who is the current chairman and president of CKST,
stated, "The Board of Directors of ClickNSettle is very impressed with the
management team of Cardo, which combines orthopedic surgical expertise with
business development acumen. Cardo is creating innovative orthopedic products
with the potential to improve patient outcomes, while offering operational
benefits to the providing orthopedic surgeons. Cardo has an established,
proprietary product portfolio, and has already demonstrated numerous promising
product development cycles. We believe Cardo is positioned to compete in a
market for orthopedic implants that is expected to grow substantially in the
coming years, as a large segment of the U.S. population begins to reach
retirement age."
About Cardo Medical, LLC
Cardo Medical, LLC, along with its wholly-owned subsidiaries, Accelerated
Innovation, LLC, Cervical Xpand, LLC and Uni-Knee, LLC, focuses on product
development, marketing and distribution of orthopedic and spinal medical
devices. The companies' product portfolio includes devices for spinal motion
preservation and fusion, hip replacement and unicompartmental knee
replacement. Cardo has received FDA clearance to market its Total Hip System,
Cervical Plate/Screw System, Spine Pedicle Screw/Rod System, Patello-femoral
Arthroplasty, and Uni-Knee Arthroplasty (UKA). Additional innovative products
are in Cardo's product pipeline pending FDA submission and clearance.
This press release contains "forward-looking statements," as that term is
defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
regarding product development efforts and other non-historical facts about
expectations, beliefs or intentions regarding the business, technologies and
products, financial condition, strategies or prospects. Many factors could
cause actual activities or results to differ materially from the activities
and results anticipated in forward-looking statements. These factors include
those described in our filings with the Securities and Exchange Commission, as
well as risks inherent in funding, developing and obtaining regulatory
approvals of new, commercially-viable and competitive products and treatments,
including the risks that any products under development may fail, may not
achieve the expected results or effectiveness and may not generate data that
would support the approval or marketing of products for the ailments being
studied or for other ailments. In addition, forward-looking statements also
may be adversely affected by general market factors, competitive product
development, product availability, federal and state regulations and
legislation, the regulatory process for new products and indications,
manufacturing issues that may arise, patent positions and litigation, among
other factors. We do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.
SOURCE clickNsettle.com, Inc.

Andrew A. Brooks, M.D., +1-310-274-2036, for Cardo Medical, LLC or
clickNsettle.com, Inc.